Multicenter Study on the Efficacy and Safety of OCS-01 in Subjects With Uveitis Related and Post Surgical Macular Edema

NCT05608837 | Active Not Recruiting Phase 2 FDA Drug

• 1 other identifier: 66881
• Study Type: interventional
• Target: 28
• Locations: 1 country
• Sites: 8

Brief Summary

The goal of the LEOPARD clinical trial is to investigate a new kind of steroid eye drops, OCS-01. Macular edema is a condition in which there is collection of fluid (edema) in the back of the eye (Macula) and it can lead to severe loss of vision. Among other causes, macular edema can happen because of a disease of the eye called Uveitis, and also after eye surgery. Treatment of macular edema remains a challenge as the condition may persist for several months and may lead to irreversible changes in the eye and poor vision. In the LEOPARD study the investigators wish to see how safe is the study drug (OCS-01) and how well it works, in resolving the fluid collection in the eye in patients with Uveitis or in patients who have had eye surgery. Participants will undergo detailed eye exam, and record their eye and medical history to see what their disease status is and if they can be included in the study based on the study criteria. If included, they will take the study drug OCS-01 in different doses for 24 weeks. During the study period, they will have regular eye exams to ensure their safety and to assess the usefulness of the study drug.

Conditions

Uveitis Related Cystoid Macular Edema; Cystoid Macular Edema, Postoperative

Keywords

Cystoid Macular Edema; Uveitis; Postoperative cystoid macular edema; Dexamethasone; Retinal diseases; Anti-Inflammatory Agents

Outcome Measures

Primary Outcomes (2)

• Central Subfield Thickness

  Mean change in central subfield thickness (CST) on optical coherence tomography (OCT) at week 12 compared to baseline.

  Baseline to 12 weeks

• Visual Acuity

  Mean change in early treatment of diabetic retinopathy study (ETDRS) best corrected visual acuity (BCVA) letter score at week 12

  Baseline to 12 weeks

Secondary Outcomes (5)

• Change in visual acuity

  Baseline to 24 weeks

• Change in visual acuity

  Week 12 and 24

• Central Subfield Thickness

  Baseline to week 24

• Visual function and quality of life

  Baseline, week 12 and week 24

• Change in macular leakage

  Baseline, week 12 and 24 weeks

Other Outcomes (3)

• Change in intraocular pressure from baseline

  8, 12 and 24 weeks

• Change in BCVA

  Weeks 8, 12 and 24

• Adverse effects

  Weeks 8, 12 and 24

Study Arms (4)

High Dose UME - 6 drops OCS-01

EXPERIMENTAL

From baseline until week 4 all participants will receive 01 drop of OCS-01, six times a day. At week 4, participants randomized to the high dose group will continue to receive 01 drop of OCS-01 six times a day until the primary end point at week 12. Starting week 12 the treatment will be administered based on the retreatment criteria until the end of study at week 24.

Drug: OCS-01

Low Dose UME 3 drops OCS-01 and 3 drops Placebo

EXPERIMENTAL

From baseline until week 4 all participants will receive 01 drop of OCS-01, six times a day. At week 4, the participants randomized to low dose group will receive 01 drop of OCS-01 three times a day and 01 drop of placebo three times a day,( total 6 drops each day) until the primary end point at week 12. Starting week 12 the treatment will be administered based on the retreatment criteria until the end of study at week 24.

Drug: OCS-01

High dose PSME - 6 drops of OCS-01

EXPERIMENTAL

From baseline until week 4 all participants will receive 01 drop of OCS-01, six times a day. At week 4, participants randomized to the high dose group will continue to receive 01 drop of OCS-01 six times a day until the primary end point at week 12. Starting week 12 the treatment will be administered based on the retreatment criteria until the end of study at week 24.

Drug: OCS-01

Low dose PSME - 3 drops of OCS-01 and 3 drops of Placebo

EXPERIMENTAL

From baseline until week 4 all participants will receive 01 drop of OCS-01, six times a day. At week 4, the participants randomized to low dose group will receive 01 drop of OCS-01 three times a day and 01 drop of placebo three times a day, (total 6 drops each day) until the primary end point at week 12. Starting week 12 the treatment will be administered based on the retreatment criteria until the end of study at week 24.

Drug: OCS-01

Interventions

OCS-01 DRUG

One drop of OCS-01 eye drops, 3-6 times daily. Dosing frequency will depend on the phase of the study.

Also known as: dexamethasone ophthalmic suspension eye drops

High Dose UME - 6 drops OCS-01; High dose PSME - 6 drops of OCS-01; Low Dose UME 3 drops OCS-01 and 3 drops Placebo; Low dose PSME - 3 drops of OCS-01 and 3 drops of Placebo

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age 18 years or older.
• Diagnosis of Uveitic macular edema (UME) or post-surgical macular edema (PSME).
• Can provide written informed consent prior to any study procedure being performed, able and willing to follow all instructions, and attend all study visits.
• UME of less than 1 years in duration or PSME of less than 1 year, with presence of intraretinal and/or subretinal fluid in the study eye, with CST of ≥ 320 µm by SD-OCT at baseline (as measured by the central reading center employing Heidelberg Spectralis spectral domain optical coherence tomography, SD-OCT). Note: Recurrent CME is also eligible if the current episode is of less than 1 year.
• An ETDRS BCVA letter score ≤ 70 (Snellen 20/40) and ≥ 35 (Snellen 20/200) in the study eye at baseline (Visit 2).
• A documented diagnosis of inactive/stable uveitis (for UME) at the screening visit.
• A trial of topical NSAID or topical corticosteroids (for PSME) for at least one consecutive month but less than 3 consecutive months before screening visit with documented treatment failure on SD-OCT or based on investigator's clinical evaluation.
• Note: If both eyes are eligible, the eye with the worse BCVA will be selected as the study eye. If both eyes have the same BCVA, the non-dominant eye will be selected.

You may not qualify if:

• Macular edema considered to be due to a cause other than UME or PSME. An eye is not considered eligible if: (1) the macular edema is considered to be related to diabetes (2) clinical exam and/or OCT suggests that vitreoretinal interface abnormalities (e.g., a taut posterior hyaloid or epiretinal membrane) are the primary cause of the macular edema, or (3) the macular edema is considered to be related to another condition such as age-related macular degeneration, retinal vein occlusion, or drug toxicity.
• A decrease in BCVA due to causes other than UME or PSME (e.g., foveal atrophy, pigment abnormalities, dense subfoveal hard exudates, previous vitreoretinal surgery, central serous retinopathy, non-retinal condition, substantial cataract, macular ischemia) that are likely to decrease BCVA by 3 lines or more (i.e., cataract would be reducing acuity to 20/40 or worse if eye was otherwise normal).
• Use of other ophthalmic formulations during the study. However, intraocular pressure (IOP) lowering eye drops are allowed if they become necessary due to increased IOP.
• History of glaucoma and documented glaucomatous optic neuropathy or clinically significant ocular hypertension in the opinion of the investigator, involving an IOP ≥ 25 mmHg on \> 3 anti-glaucoma medications in the study eye.
• Any other ocular disease that could cause substantial reduction in BCVA, including retinal detachment, epiretinal membrane, vitreous hemorrhage or fibrosis involving the macula in the study eye, other retinal inflammatory or infectious diseases.
• Active peri-ocular or ocular infection (e.g., blepharitis, keratitis, scleritis, or conjunctivitis).
• History of infectious uveitis.
• High myopia (-8 diopter or more correction) in the study eye.
• Any form of diabetic retinopathy.
• History of increased intraocular pressure with topical steroid therapy.
• Pregnancy/Breastfeeding
• For UME:
• Active uveitis as determined by the presence of anterior chamber cells or vitreous cells.
• Unstable (increasing) dose of immunosuppressives during 2 months prior to the baseline visit. Immunosuppressives are defined as antimetabolites (methotrexate, mycophenolate mofetil, azathioprine, cyclosporine and tacrolimus, among others) and biologics (including adalimumab, infliximab, tocilizumab, golimumab, secukinumab and rituximab, and others).
• Treated with more than 2 types of immunosuppressives (excluding steroids) within 2 months prior to baseline visit.

Sponsors & Collaborators

• Quan Dong Nguyen: lead
• Global Ophthalmic Research Center (GORC): collaborator
• Oculis: collaborator

Study Sites (8)

Retina Vitreous Associates Medical Group

Beverly Hills, California, 90211, United States

Location

Retina Associates of Southern California

Huntington Beach, California, 92647, United States

Location

Stein Eye Institute at UCLA

Los Angeles, California, 90095, United States

Location

Byers Eye Institute at Stanford

Palo Alto, California, 94303, United States

Location

Massachusetts Eye Research and Surgery Institution

Boston, Massachusetts, 02451, United States

Location

Erie Retina Research

Erie, Pennsylvania, 16507, United States

Location

Valley Retina Institute P.A

McAllen, Texas, 78503, United States

Location

Texas Retina Associates

Plano, Texas, 75075, United States

Location

MeSH Terms

Conditions

Macular Edema; Uveitis; Retinal Diseases

Condition Hierarchy (Ancestors)

Macular Degeneration; Retinal Degeneration; Eye Diseases; Uveal Diseases

Study Officials

• Quan D Nguyen, MD, MSc

  Stanford University

  STUDY CHAIR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, OUTCOMES ASSESSOR
• Masking Details: BCVA examiner and study subjects will be masked
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Professor of Ophthalmology

Study Record Dates

• First Submitted: November 1, 2022
• First Posted: November 8, 2022
• Study Start: May 26, 2023
• Primary Completion (Estimated): June 1, 2026
• Study Completion (Estimated): September 1, 2026
• Last Updated: May 25, 2025

Record last verified: 2025-05

Data Sharing

• IPD Sharing: Will not share

Locations

US (8)